Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1986 Jun;39(6):677–679. doi: 10.1136/jcp.39.6.677

Myelofibrosis complicated by intestinal extramedullary haemopoiesis and acute small bowel obstruction.

S MacKinnon, A M McNicol, F D Lee, G A McDonald
PMCID: PMC499992  PMID: 3722421

Abstract

A 78 year old woman with myelofibrosis presented with an acute small bowel obstruction. Pathology of the resected small bowel showed extramedullary haemopoiesis leading to acute small bowel obstruction. As far as we know this is the first such reported case.

Full text

PDF
677

Images in this article

678Image
on p.678
678Image
on p.678

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burstein S. A., Malpass T. W., Yee E., Kadin M., Brigden M., Adamson J. W., Harker L. A. Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis. Br J Haematol. 1984 Jul;57(3):383–392. doi: 10.1111/j.1365-2141.1984.tb02912.x. [DOI] [PubMed] [Google Scholar]
  2. DAMESHEK W. Some speculations on the myeloproliferative syndromes. Blood. 1951 Apr;6(4):372–375. [PubMed] [Google Scholar]
  3. Fialkow P. J., Faguet G. B., Jacobson R. J., Vaidya K., Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood. 1981 Nov;58(5):916–919. [PubMed] [Google Scholar]
  4. Glew R. H., Haese W. H., McIntyre P. A. Myeloid metaplasia with myelofibrosis. The clinical spectrum of extramedullary hematopoiesis and tumor formation. Johns Hopkins Med J. 1973 May;132(5):253–270. [PubMed] [Google Scholar]
  5. Groopman J. E. The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann Intern Med. 1980 Jun;92(6):857–858. doi: 10.7326/0003-4819-92-6-857. [DOI] [PubMed] [Google Scholar]
  6. Jacobson R. J., Salo A., Fialkow P. J. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood. 1978 Feb;51(2):189–194. [PubMed] [Google Scholar]
  7. LIEBERMAN P. H., ROSVOLL R. V., LEY A. B. EXTRAMEDULLARY MYELOID TUMORS IN PRIMARY MYELOFIBROSIS. Cancer. 1965 Jun;18:727–736. doi: 10.1002/1097-0142(196506)18:6<727::aid-cncr2820180610>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  8. RUEBNER B. Myelosclerosis with serosal myeloid metaplasia and fatal liver involvement. Ann Intern Med. 1960 Nov;53:1075–1088. doi: 10.7326/0003-4819-53-5-1075. [DOI] [PubMed] [Google Scholar]
  9. Scher C. D., Shepard R. C., Antoniades H. N., Stiles C. D. Platelet-derived growth factor and the regulation of the mammalian fibroblast cell cycle. Biochim Biophys Acta. 1979 Aug 10;560(2):217–241. doi: 10.1016/0304-419x(79)90020-9. [DOI] [PubMed] [Google Scholar]
  10. Silverstein M. N., Linman J. W. Causes of death in agnogenic myeloid metaplasia. Mayo Clin Proc. 1969 Jan;44(1):36–39. [PubMed] [Google Scholar]
  11. Van Slyck E. J., Weiss L., Dully M. Chromosomal evidence for the secondary role of fibroblastic proliferation in acute myelofibrosis. Blood. 1970 Dec;36(6):729–735. [PubMed] [Google Scholar]
  12. Ward H. P., Block M. H. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 1971 Sep;50(5):357–420. doi: 10.1097/00005792-197109000-00001. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES